Post-initiation chlorophyllin exposure does not modulate aflatoxin-induced foci in the liver and colon of rats

Journal of Carcinogenesis

Volumn 5, Issue , 2006, Pages

  Orner, Gayle A ^a   Roebuck, Bill D ^b   Dashwood, Roderick H ^a,c   Bailey, George S ^a,c  

^a OREGON STATE UNIVERSITY   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c OREGON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN B1; CARCINOGEN; CHLOROPHYLL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHEMOPROPHYLAXIS; COLON; COMPLEX FORMATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EXPOSURE; DRUG MECHANISM; LIVER; MALE; NONHUMAN; RAT;

EID: 33144466126     PISSN: 14773163     EISSN: None     Source Type: Journal    
DOI: 10.1186/1477-3163-5-6     Document Type: Article

References (30)

1. Dashwood RH: Chlorophylls as anticarcinogens. International Journal of Oncology 1997, 10:721-727.
2. Egner PA, Wang JB, Zhu YR, Zhang BC, Wu Y, Zhang QN, Qian GS, Kuang SY, Gange SJ, Jacobson LP; Helzlsouer KJ, Bailey GS, Groopman JD, Kensler TW: Chlorophyllin intervention reduces aflatoxin-DNA adducts in individuals at high risk for liver cancer. Proc. Natl Acad Sci U S A 2001, 98(25):14601-14606.
3. Xu M, Orner GA, Bailey GS, Stoner GD, Horio DT, Dashwood RH: Post-initiation effects of chlorophyllin and indole-3-carbinol in rats given 1,2-dimethylthydrazine or 2-amino-3-methylimidazo. Carcinogenesis 2001, 22(2):309-314.
4. Nelson RL: Chlorophyllin, an antimutagen, acts as a tumor promoter in the rat-dimethylhydrazine colon carcinogenesis model. Anticancer Res 1992, 12(3):737-739.
5. Diaz GD, Li Q, Dashwood RH: Caspase-8 and apoptosis-inducing factor mediate a cytochrome c-independent pathway of apoptosis in human colon cancer cells induced by the dietary phytochemical chlorophyllin. Cancer Res 2003, 63(6):1254-1261.
6. Yun CH, Jeong HG, Jhoun JW, Guengerich FP: Non-specific inhibition of cytochrome P450 activities by chlorophyllin in human and rat liver microsomes. Carcinogenesis 1995, 16(6):1437-1440.
7. Dingley KH, Ubick EA, Chiarappa-Zucca ML, Nowell S. Abel S, Ebeler SE, Mitchell AE, Burns SA, Steinberg FM, Clifford AJ: Effects of dietary constituents with chemopreventive potential on adduct formation of a low dose of the heterocyclic amines PhlP and IQ and phase II hepatic enzymes. Nutr Cancer 2003, 46(2):212-221.
8. Fahey JW, Stephenson KK, Dinkova-Kostova AT, Egner PA, Kensler TW, Talalay P: Chlorophyll, chlorophyllin and related tetrapyrroles are significant inducers of mammalian phase 2 cytoprotective genes. Carcinogenesis 2005, 26(7):1247-1255.
9. Kensler TW, Egner PA, Davidson NE, Roebuck BD, Pikul A, Groopman JD: Modulation of aflatoxin metabolism, aflatoxin-N7-guanine formation, and hepatic tumorigenesis in rats fed ethoxyquin: role of induction of glutathione S-transferases. Cancer Res 1986, 46(8):3924-3931.
10. Sato Y, Mukai K, Watanabe S, Goto M, Shimosato Y: The AMeX method. A simplified technique of tissue processing and paraffin embedding with improved preservation of antigens for immunostaining. Am J Pathol 1986, 125(3):431-435.
11. Maxuitenko YY, Curphey TJ, Kensler TW, Roebuck BD: Protection against aflatoxin BI-induced hepatic toxicity as short-term screen of cancer chemopreventive dithiolethiones. Fundam Appl Toxicol 1996, 32(2):250-259.
12. Pugh TD, King JH, Koen H, Nychka D, Chover J, Wahba G, He YH, Goldfarb S: Reliable stereological method for estimating the number of microscopic hepatocellular foci from their transections. Cancer Res 1983, 43(3):1261-1268.
13. Tachino N, Hayashi R, Liew C, Bailey G, Dashwood R: Evidence for ras gene mutation in 2-amino-3-methylimidazo[4,5-f]quinoline-induced colonic aberrant crypts in the rat. Mol Carcinog 1995, 12(4):187-192.
14. Dashwood RH, Xu M, Orner GA, Horio DT. Colonic cell proliferation, apoptosis and aberrant crypt foci development in rats given 2-amino-3-methylimidazo[4,5-f]quinoline and treated post initiation with chlorophyllin. Eur J Cancer Prev 2001, 10(2):139-145.
15. Newberne PM, Suphakarn V: Preventive role of vitamin A in colon carcinogenesis in rats. Cancer 1977, 40(5 Suppl):2553-2556.
16. Suphakarn VS, Newberne PM, Goldman M: Vitamin A and aflatoxin: effect on liver and colon cancer. Nutr Cancer 1983, 5(1):41-50.
17. Ward JM, Sontag JM, Weisburger EK, Brown CA: Effect of lifetime exposure to aflatoxin bl in rats. J Natl Cancer Inst 1975, 55(1):107-113.
18. Deger GE: Letter: Aflatoxin-human colon carcinogenesis? Ann Intern Med 1976, 85(2):204-205.
19. Harrison JC, Carvajal M, Garner RC: Does aflatoxin exposure in the United Kingdom constitute a cancer risk? Environ Health Perspect 1993, 99:99-105.
20. Roebuck BD, Liu YL, Rogers AE, Groopman JD, Kensler TW: Protection against aflatoxin BI-induced hepatocarcinogenesis in F344 rats by 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione (oltipraz): predictive role for short-term molecular dosimetry. Cancer Res 1991, 51(20):5501-5506.
21. Corpet DE, Tache S: Most effective colon cancer chemopreventive agents in rats: a systematic review of aberrant crypt foci and tumor data, ranked by potency. Nutr Cancer 2002, 43(1):1-21.
22. Caderni G, Femia AP, Giannini A, Favuzza A, Luceri C, Salvadori M, Dolara P: Identification of mucin-depleted foci in the unsectioned colon of azoxymethane-treated rats: correlation with carcinogenesis. Cancer Res 2003, 63(10):2388-2392.
23. Yoshimi N, Morioka T, Kinjo T, Inamine M, Kaneshiro T, Shimizu T, Suzui M, Yamada Y, Mori H: Histological and immunohistochemical observations of mucin-depleted foci (MDF) stained with Alcian blue, in rat colon carcinogenesis induced with 1,2-dimethylhydrazine dihydrochloride. Cancer Sci 2004, 95(10):792-797.
24. Yamada Y, Yoshimi N, Hirose Y, Kawabata K, Matsunaga. K, Shimizu M, Hara A, Mori H: Frequent beta-catenin gene mutations and accumulations of the protein in the putative preneoplastic lesions lacking macroscopic aberrant crypt foci appearance, in rat colon carcinogenesis. Cancer Res 2000, 60(13):3323-3327.
25. Yamada Y, Yoshimi N, Hirose Y, Matsunaga K, Katayama M, Sakata K, Shimizu M, Kuno T, Mori H: Sequential analysis of morphological and biological properties of beta- catenin-accumulated crypts, provable premalignant lesions independent of aberrant crypt foci in rat colon carcinogenesis. Cancer Res 2001, 61(5):1874-1878.
26. Paulsen JE, Namork E, Steffensen IL, Eide TJ, Alexander J: Identification and quantification of aberrant crypt foci in the colon of Min mice - a murine model of familial adenomatous polyposis. Scand J Gastroenterol 2000, 35(5):534-539.
27. Bird RP: Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett 1987, 37(2):147-151.
28. Nascimbeni R, Villanacci V, Mariani PP, Di Betta F, Ghirardi M, Donato F, Salerni B: Aberrant crypt foci in the human colon: frequency and histologic patterns in patients with colorectal cancer or diverticular disease. Am J Surg Pathol 1999, 23(10):1256-1263.
29. Bouzourene H, Chaubert P, Seelentag W, Bosman FT, Saraga E: Aberrant crypt foci in patients with neoplastic and nonneoplastic colonic disease. Hum Pathol 1999, 30(1):66-71.
30. Rudolph RE, Dominitz JA, Lampe JW, Levy L, Qu P, Li SS, Lampe PD, Bronner MP, Potter JD: Risk factors for colorectal cancer in relation to number and size of aberrant crypt foci in humans. Cancer Epidemiol Biomarkers Prev 2005, 14(3):605-608.